The benefit of IgA is stronger FcR signaling, and the presence of both Fcα and Fcγ would give the resulting chimeric antibodies the ability to bind to a greater number of FcR molecules than the parental antibodies, resulting in the increased killing of target cells, such as cancer. This evidence concerns the gene CD79A and cancer.